A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

NCT07748624 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

VEXAS Syndrome

Interventions

DRUG: Arumakimig
DRUG: Placebo
DRUG: Oral glucocorticoids

Sponsor

Novartis Pharmaceuticals